Cargando…
Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial
Autores principales: | Butler, Javed, Siddiqi, Tariq Jamal, Anker, Stefan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826001/ https://www.ncbi.nlm.nih.gov/pubmed/36088540 http://dx.doi.org/10.1002/ejhf.2684 |
Ejemplares similares
-
Patiromer for the management of hyperkalemia in heart failure with reduced
ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022) -
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021) -
Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
por: Packer, Milton, et al.
Publicado: (2023) -
Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020) -
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)